GB0303289D0 - Combination therapy - Google Patents

Combination therapy

Info

Publication number
GB0303289D0
GB0303289D0 GB0303289A GB0303289A GB0303289D0 GB 0303289 D0 GB0303289 D0 GB 0303289D0 GB 0303289 A GB0303289 A GB 0303289A GB 0303289 A GB0303289 A GB 0303289A GB 0303289 D0 GB0303289 D0 GB 0303289D0
Authority
GB
United Kingdom
Prior art keywords
combination therapy
therapy
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0303289A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to GB0303289A priority Critical patent/GB0303289D0/en
Publication of GB0303289D0 publication Critical patent/GB0303289D0/en
Priority to AU2004212255A priority patent/AU2004212255B2/en
Priority to KR1020107027024A priority patent/KR20110006699A/en
Priority to DE602004032310T priority patent/DE602004032310D1/en
Priority to NZ541297A priority patent/NZ541297A/en
Priority to MXPA05008583A priority patent/MXPA05008583A/en
Priority to AT04710081T priority patent/ATE506062T1/en
Priority to PT04710081T priority patent/PT1592423E/en
Priority to CA2514227A priority patent/CA2514227C/en
Priority to SI200431690T priority patent/SI1592423T1/en
Priority to DK04710081.3T priority patent/DK1592423T3/en
Priority to KR1020057014913A priority patent/KR20050100683A/en
Priority to BR0407301-0A priority patent/BRPI0407301A/en
Priority to PCT/GB2004/000550 priority patent/WO2004071397A2/en
Priority to US10/543,106 priority patent/US20060142316A1/en
Priority to CNB200480009817XA priority patent/CN100502866C/en
Priority to EP04710081A priority patent/EP1592423B1/en
Priority to JP2006502268A priority patent/JP2006517575A/en
Priority to ES04710081T priority patent/ES2364030T3/en
Priority to IL169702A priority patent/IL169702A/en
Priority to NO20053649A priority patent/NO331486B1/en
Priority to ZA200506211A priority patent/ZA200506211B/en
Priority to HK06104405.5A priority patent/HK1084032A1/en
Priority to US12/501,599 priority patent/US20100130520A1/en
Priority to JP2010238996A priority patent/JP5563950B2/en
Priority to US12/973,271 priority patent/US20110086870A1/en
Priority to CY20111100565T priority patent/CY1111565T1/en
Priority to US13/282,750 priority patent/US20120252826A1/en
Priority to JP2014010618A priority patent/JP2014065750A/en
Ceased legal-status Critical Current

Links

GB0303289A 2003-02-13 2003-02-13 Combination therapy Ceased GB0303289D0 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
GB0303289A GB0303289D0 (en) 2003-02-13 2003-02-13 Combination therapy
ES04710081T ES2364030T3 (en) 2003-02-13 2004-02-11 COMBINATION THERAPY OF ZD6474 WITH 5-FU AND / OR CPT-11.
US10/543,106 US20060142316A1 (en) 2003-02-13 2004-02-11 Combination therapy
EP04710081A EP1592423B1 (en) 2003-02-13 2004-02-11 Combination therapy of zd6474 with 5-fu and/or cpt-11
CNB200480009817XA CN100502866C (en) 2003-02-13 2004-02-11 Combination therapy
NZ541297A NZ541297A (en) 2003-02-13 2004-02-11 Combination therapy of ZD6474 with 5-FU or/and CPT-11
KR1020107027024A KR20110006699A (en) 2003-02-13 2004-02-11 Combination therapy of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline with 5-flurouracil or/and irinotecan
AT04710081T ATE506062T1 (en) 2003-02-13 2004-02-11 COMBINATION THERAPY OF ZD6474 WITH 5-FU OR/AND CPT-11
PT04710081T PT1592423E (en) 2003-02-13 2004-02-11 Combination therapy of zd6474 with 5-fu and/or cpt-11
CA2514227A CA2514227C (en) 2003-02-13 2004-02-11 Combination therapy of zd6474 with 5-fu or/and cpt-11
SI200431690T SI1592423T1 (en) 2003-02-13 2004-02-11 Combination therapy of zd6474 with 5-fu and/or cpt-11
DK04710081.3T DK1592423T3 (en) 2003-02-13 2004-02-11 Combination therapy of ZD6474 with 5-FU and / or CPT-11
KR1020057014913A KR20050100683A (en) 2003-02-13 2004-02-11 Combination therapy of zd6474 with 5-fu or/and cpt-11
JP2006502268A JP2006517575A (en) 2003-02-13 2004-02-11 Combination therapy
PCT/GB2004/000550 WO2004071397A2 (en) 2003-02-13 2004-02-11 Combination therapy of zd6474 with 5-fu or/and cpt-11
AU2004212255A AU2004212255B2 (en) 2003-02-13 2004-02-11 Combination therapy of ZD6474 with 5-FU or/and CPT-11
DE602004032310T DE602004032310D1 (en) 2003-02-13 2004-02-11 COMBINATION THERAPY OF ZD6474 WITH 5-FU OR / AND CPT-11
MXPA05008583A MXPA05008583A (en) 2003-02-13 2004-02-11 Combination therapy of zd6474 with 5-fu or/and cpt-11.
BR0407301-0A BRPI0407301A (en) 2003-02-13 2004-02-11 Use of a combination, pharmaceutical composition, kit, and method for treating cancer in a warm-blooded animal such as a human.
IL169702A IL169702A (en) 2003-02-13 2005-07-17 Use of zd6474 with 5-fu or/and cpt-11 in the manufacture of medicaments for the treatment of cancer and pharmaceutical compositions and kits comprising the same
NO20053649A NO331486B1 (en) 2003-02-13 2005-07-27 Use of 4- (4-bromo-2-fluoroanilino) -6-methoxy-7- (1-methylpiperidin-4-ylmethoxy) quinazoline also known as ZD6474, or a pharmaceutically acceptable salt thereof and ± n of: a) 5- FU; b) CPT-11; and c) 5-FU and CPT-11, in the manufacture of a medicament for use in the treatment of cancer in a warm-blooded animal such as a human, as well as a pharmaceutical composition and kits containing the same
ZA200506211A ZA200506211B (en) 2003-02-13 2005-08-03 Combination therapy of ZD6474 with 5-FU or/and CT-11
HK06104405.5A HK1084032A1 (en) 2003-02-13 2006-04-11 Combination therapy of zd6474 with 5-fu and/or cpt-11
US12/501,599 US20100130520A1 (en) 2003-02-13 2009-07-13 Combination therapy
JP2010238996A JP5563950B2 (en) 2003-02-13 2010-10-25 Combination therapy
US12/973,271 US20110086870A1 (en) 2003-02-13 2010-12-20 Combination Therapy
CY20111100565T CY1111565T1 (en) 2003-02-13 2011-06-15 ZD6474 5-FU AND / OR CPT-11 COMBINATION TREATMENT
US13/282,750 US20120252826A1 (en) 2003-02-13 2011-10-27 Combination Therapy
JP2014010618A JP2014065750A (en) 2003-02-13 2014-01-23 Combination therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0303289A GB0303289D0 (en) 2003-02-13 2003-02-13 Combination therapy

Publications (1)

Publication Number Publication Date
GB0303289D0 true GB0303289D0 (en) 2003-03-19

Family

ID=9952942

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0303289A Ceased GB0303289D0 (en) 2003-02-13 2003-02-13 Combination therapy

Country Status (4)

Country Link
CN (1) CN100502866C (en)
ES (1) ES2364030T3 (en)
GB (1) GB0303289D0 (en)
ZA (1) ZA200506211B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103265529A (en) * 2013-05-22 2013-08-28 苏州明锐医药科技有限公司 Preparation method of vandetanib
CN104876852B (en) * 2014-02-28 2017-09-26 上海医药工业研究院 ZD6474 midbody compound and preparation method thereof

Also Published As

Publication number Publication date
CN1774248A (en) 2006-05-17
ES2364030T3 (en) 2011-08-23
CN100502866C (en) 2009-06-24
ZA200506211B (en) 2006-05-31

Similar Documents

Publication Publication Date Title
GB0307918D0 (en) Therapeutic use
GB0303910D0 (en) Therapeutic agents
GB0308318D0 (en) Therapeutic agents
GB0313250D0 (en) Therapeutic agents
GB0218526D0 (en) Combination therapy
GB0326486D0 (en) Combination treatment
GB0314049D0 (en) Therapeutic agents
GB0311859D0 (en) Therapeutic agents
GB0311201D0 (en) Therapeutic agents
GB0301350D0 (en) Therapeutic agents
IL172632A0 (en) Therapeutic agents
GB0304524D0 (en) Therapeutic agents
GB0303289D0 (en) Combination therapy
GB0325021D0 (en) Therapeutic combinations
GB0316184D0 (en) Combination therapy
GB0314097D0 (en) Combination therapy
GB0307560D0 (en) Combination therapy
GB0329512D0 (en) Combination therapy
GB0318311D0 (en) Combination therapy
GB0316181D0 (en) Combination therapy
GB0316176D0 (en) Combination therapy
GB0314100D0 (en) Combination therapy
GB0313363D0 (en) Therapeutic combinations
GB0208680D0 (en) Combination therapy
GB0218388D0 (en) Combination therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)